Free Trial
NASDAQ:CLRB

Cellectar Biosciences (CLRB) Stock Price, News & Analysis

Cellectar Biosciences logo
$4.88 -0.05 (-1.01%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$4.89 +0.01 (+0.12%)
As of 07/11/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cellectar Biosciences Stock (NASDAQ:CLRB)

Key Stats

Today's Range
$4.80
$5.05
50-Day Range
$4.70
$13.85
52-Week Range
$4.36
$94.50
Volume
61,373 shs
Average Volume
145,169 shs
Market Capitalization
$8.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$375.00
Consensus Rating
Hold

Company Overview

Cellectar Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

CLRB MarketRank™: 

Cellectar Biosciences scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cellectar Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cellectar Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cellectar Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Cellectar Biosciences are expected to grow in the coming year, from ($1.59) to ($0.72) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cellectar Biosciences is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cellectar Biosciences is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cellectar Biosciences has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Cellectar Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    6.35% of the float of Cellectar Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cellectar Biosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cellectar Biosciences has recently increased by 140.17%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cellectar Biosciences does not currently pay a dividend.

  • Dividend Growth

    Cellectar Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.35% of the float of Cellectar Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cellectar Biosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cellectar Biosciences has recently increased by 140.17%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cellectar Biosciences has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Cellectar Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for CLRB on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cellectar Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $124,750.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 5.04% of the stock of Cellectar Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 16.41% of the stock of Cellectar Biosciences is held by institutions.

  • Read more about Cellectar Biosciences' insider trading history.
Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLRB Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Headlines

CLRB Stock Analysis - Frequently Asked Questions

Cellectar Biosciences' stock was trading at $8.97 at the beginning of the year. Since then, CLRB stock has decreased by 45.6% and is now trading at $4.88.

Cellectar Biosciences, Inc. (NASDAQ:CLRB) posted its quarterly earnings results on Tuesday, May, 13th. The biopharmaceutical company reported ($3.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($5.10) by $1.20.
Read the conference call transcript
.

Cellectar Biosciences's stock reverse split on the morning of Friday, July 22nd 2022.The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectar Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), HudBay Minerals (HBM), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and CymaBay Therapeutics (CBAY).

Company Calendar

Last Earnings
5/13/2025
Today
7/13/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CLRB
CIK
1279704
Employees
10
Year Founded
N/A

Price Target and Rating

High Price Target
$390.00
Low Price Target
$360.00
Potential Upside/Downside
+7,584.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($21.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$44.58 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-619.70%
Return on Assets
-158.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.47
Quick Ratio
2.47

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.98 per share
Price / Book
0.54

Miscellaneous

Outstanding Shares
1,810,000
Free Float
1,719,000
Market Cap
$8.83 million
Optionable
Optionable
Beta
0.51
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:CLRB) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners